OmniAb, Inc. Common Stock (OABI) Stock Price
OABIStock
$4.59+170.00%52W
Market Cap$667.34M
P/E—
PEG Ratio—
Div yield—
Beta0.61
OABI Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)204.48%
Price vs S&P 500 (4W)1.54%
VGM Score56.97
OABI Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.13 | -$0.05 | +60.78%(+$0.08) | |
| Q1 2026 | -$0.10 | -$0.06 | +37.93%(+$0.04) | |
| Q4 2025 | -$0.09 | -$0.11 | -25.71%(-$0.02) | |
| Q3 2025 | -$0.14 | -$0.14 | -2.94%(-$0.00) | |
| Q2 2025 | -$0.15 | -$0.15 | +1.10%(+$0.00) |
OABI Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.23
4.23
4.23
4.23
Industry Peers — R&D — Physical Sciences(17)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
OABIOmniAb, Inc. Common Stock | F | B | A | — | -16.6% | -4.3% | — | $4.59 |
| IQVIQVIA Holdings Inc. | D | C | A | 32.3x | 21.9% | 7.5% | — | $266.90 |
| INCYIncyte Genomics Inc | C | B | B | 17.8x | 29.6% | 14.0% | — | $113.07 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | 38.3x | 110.2% | 22.3% | — | $618.47 |
| CRLCharles River Laboratories International, Inc. | F | D | A | — | -7.7% | 6.5% | — | $300.15 |
| ICLRIcon Plc | C | C | B | 57.3x | 0.8% | 24.1% | — | $170.18 |
| ABSIAbsci Corporation Common Stock | F | F | B | — | -59.2% | -10.1% | — | $8.25 |
| NRCNRC Health Common Stock | D | D | B | 38.4x | 48.5% | 0.6% | 1.2% | $20.15 |
| MXCTMaxCyte, Inc. Common Stock | C | D | B | — | -21.0% | 4.8% | — | $1.30 |
| IBACIB Acquisition Corp. Common Stock | — | D | C | 15.9x | -3.7% | — | — | $10.86 |
| ONMDOneMedNet Corp Class A Common Stock | D | A | D | — | -6.8% | — | — | $4.51 |
About OmniAb, Inc. Common Stock
OmniAb licenses antibody discovery technology to pharmaceutical and biotech companies and academic institutions. The platform uses engineered transgenic animals powered by proprietary Biological Intelligence to rapidly identify optimized antibody candidates for drug development. The company generates revenue through licensing agreements that accelerate its partners' therapeutic discovery efforts.